首页> 外文期刊>Tropical Journal of Pharmaceutical Research >Daidzin decreases blood glucose and lipid in streptozotocin-induced diabetic mice
【24h】

Daidzin decreases blood glucose and lipid in streptozotocin-induced diabetic mice

机译:大豆苷可降低链脲佐菌素诱导的糖尿病小鼠的血糖和血脂

获取原文
       

摘要

Purpose: To investigate the ameliorative effect of daidzin (DZ) on diabetes in streptozotocin (STZ)-induced diabetic Institute of Cancer Research (ICR) mice, with a view to determining its usefulness in the treatment of diabetes. Methods: The effect of DZ (100, 200 and 400 mg/kg) on blood glucose was investigated in both normal and STZ-induced diabetic mice with glibenclamide (3 mg/kg) and metformin (400 mg/kg) as positive control, respectively. Serum or hepatic levels of lipid, proinflammatory factors, malondialdehyde (MDA) and superoxide dismutase (SOD) were measured. Glucosidase activity assay and glucose uptake by C2C12 myotubes were performed in vitro and the ex pression of glucose transporter 4 (GLUT4) in C2C12 cells was determined by western blot. Results: DZ (200 and 400 mg/kg) did not decrease fasting blood glucose in normal mice but inhibited starch-induced postprandial glycemia. Oral administration of 400 mg/kg of DZ for 14 days significantly decreased mouse blood glucose (p 0.01), as well as serum total cholesterol (TC, p 0.01), triglycerides (TG, p 0.01), low-density lipoprotein cholesterol (LDL-c, p 0.01) levels in STZ-induced hyperglycemic mice and improved oral glucose tolerance. The serum and hepatic activity of SOD was enhanced (p 0.01 and p 0.001, respectively) while MDA level decreased (p 0.001). Blood concentrations of interleukin-6 (IL-6, p 0.001), tumor necrosis factor α (TNF-α, p 0.01), monocyte chemotactic protein 1 (MCP-1, p 0.01) were also significantly reduced. In vitro glucosidase activity results showed that DZ inhibited α-glucosidase with IC50 values of 82, 98 and 389 μg/mL for α-glucosidase from S. cerevisiae, Rhizopus sp. and rat intestines, respectively. It also stimulated glucose uptake and GLUT4 membrane translocation in C2C12 myotubes at 20 μM (p 0.05). Conclusion: Oral administration of DZ is effective in alleviating diabetic hyperglycemia, dyslipidemia and inflammation. Inhibition of α-glucosidase and stimulation of glucose consumption by muscles may account for its inhibitory effect on blood glucose.
机译:目的:研究大豆苷(DZ)对链脲佐菌素(STZ)诱导的糖尿病癌症研究所(ICR)小鼠的糖尿病的改善作用,以确定其在糖尿病治疗中的作用。方法:以格列本脲(3 mg / kg)和二甲双胍(400 mg / kg)为阳性对照,在正常和STZ诱导的糖尿病小鼠中研究DZ(100、200和400 mg / kg)对血糖的影响,分别。测量血清或肝脏中的脂质,促炎因子,丙二醛(MDA)和超氧化物歧化酶(SOD)的水平。体外进行葡萄糖苷酶活性测定和C2C12肌管摄取葡萄糖,并通过蛋白质印迹法测定C2C12细胞中葡萄糖转运蛋白4(GLUT4)的表达。结果:DZ(200和400 mg / kg)不能降低正常小鼠的空腹血糖,但可以抑制淀粉诱导的餐后血糖。口服14天400 mg / kg的DZ可显着降低小鼠血糖(p <0.01),血清总胆固醇(TC,p <0.01),甘油三酸酯(TG,p <0.01),低密度脂蛋白STZ诱导的高血糖小鼠体内的胆固醇(LDL-c,p <0.01)水平和改善的口服葡萄糖耐量。 SOD的血清和肝脏活性增强(分别为p <0.01和p <0.001),而MDA水平降低(p <0.001)。白细胞介素6(IL-6,p <0.001),肿瘤坏死因子α(TNF-α,p <0.01),单核细胞趋化蛋白1(MCP-1,p <0.01)的血药浓度也显着降低。体外葡萄糖苷酶活性结果表明,DZ抑制了酿酒酵母Rhizopus sp。的α-葡萄糖苷酶的IC50值分别为82、98和389μg/ mL。和大鼠的肠子。它还以20μM刺激C2C12肌管中的葡萄糖摄取和GLUT4膜移位(p <0.05)。结论:口服DZ可有效缓解糖尿病高血糖,血脂异常和炎症。抑制α-葡萄糖苷酶和刺激肌肉消耗葡萄糖可解释其对血糖的抑制作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号